Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 9, Issue 7, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac283
Keywords
COVID-19; immunocompromised hosts; monoclonal antibodies; transplant infectious diseases
Categories
Funding
- Mayo Clinic
- Mayo Clinic Department of Medicine Catalyst Award for Advancing in Academics
Ask authors/readers for more resources
This study reports the clinical characteristics of patients who developed COVID-19 shortly after receiving Tixagevimab-cilgavimab, highlighting the need for additional measures to prevent COVID-19 during periods of high transmission of the SARS-CoV-2 virus.
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
